Newsroom | 18711 results
Sorted by: Latest
-
Concentra Expands into Idaho with Opening of Boise Medical Center
DALLAS & BOISE, Idaho--(BUSINESS WIRE)--Concentra® (NYSE: CON), the nation's leader in occupational and workforce health services, today announced the opening of its first Idaho medical center, expanding access to workforce health solutions for employers and employees throughout the Boise region. The new medical center is in Federal Way Plaza at 3237 South Federal Way, Boise, Idaho 83705, providing convenient access for employers and employees throughout the city and the surrounding Treasure Va...
-
Kalogon Launches Verro, a New Medicare-coded Custom Wheelchair Cushion Built for the Most Complex Support Needs
MELBOURNE, Fla.--(BUSINESS WIRE)--Kalogon expands its seating line with Verro, a Medicare-coded custom cushion engineered for wheelchair users with complex postural needs....
-
Radiology Partners Strengthens RP Clinical Services Leadership with Matt Peterson as President and Krishna Nallamshetty, MD, as Chief Operating Officer
NASHVILLE, Tenn.--(BUSINESS WIRE)--Radiology Partners, Inc. (RP), through RP Clinical Services and its affiliated practices, today announced two leadership appointments, effective July 20. Matt Peterson has been named President of RP Clinical Services, reporting to Rich Whitney, Chairman and Chief Executive Officer of RP. Krishna Nallamshetty, MD, will become full-time Chief Operating Officer of RP Clinical Services after serving as Interim COO since December, and will also serve as Interim Chi...
-
Kinaset Therapeutics Announces First Patient Dosed in Phase 2b PANAIRAMA Trial of frevecitinib (KN-002) in Patients with Severe Asthma
BOSTON--(BUSINESS WIRE)--Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, today announced the first patient has been dosed in its Phase 2b clinical trial evaluating frevecitinib, a novel inhaled pan JAK inhibitor, in patients with severe asthma inadequately controlled despite treatment with medium-to-high dose inhaled corticosteroid long-acting beta agonist (ICS/LABA) therapy. PANAIRAMA is a randomized, doubl...
-
HealthTrust Launches Signal, A New AI-Powered Intelligence for Health Systems
NASHVILLE, Tenn.--(BUSINESS WIRE)--HealthTrust Performance Group™ (HealthTrust) today announced the launch of Signal, an AI-powered intelligence platform that continuously synthesizes data from multiple sources—with the goal of empowering healthcare leaders to uncover opportunities, identify risks and take informed, measurable actions quickly. Healthcare organizations are managing an increasing volume of data across fragmented systems, making it difficult to generate timely insights and act wit...
-
GE HealthCare introduces MIM Anyware to extend remote access to imaging data and optimize clinical collaboration
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the introduction of MIM Anyware™, a remote access platform that provides secure, healthcare system-controlled access to imaging data through a web browser without requiring local software installation. By enabling authorized users to access MIM software applications from virtually any location, MIM Anyware is designed to support collaboration across departments and clinical decision-making. Today, healthcare systems are mana...
-
Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today provided an update on the anticipated timing of a Committee for Medicinal Products for Human Use (CHMP) opinion for the apitegromab marketing authorisation application (MAA) for children and adults with spinal muscular atrophy (S...
-
Aptar Pharma Launches Integrated System-Level Framework to Support Injectable Drug Development
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Pharma introduces a partner-based system-level framework to support injectable development decisions...
-
Cutera® and Restimulate Health™ Announce Strategic Partnership to Advance Rehabilitation with truFlex Technology
BRISBANE, Calif.--(BUSINESS WIRE)--CUTERA, INC., a leading provider of aesthetic and dermatologic solutions, today announced a strategic partnership with Restimulate Health, an innovative healthcare provider focused on optimizing rehabilitation outcomes. Through this collaboration, Restimulate Health will incorporate Cutera’s truFlex technology into its clinically developed proprietary neuromuscular activation protocols to support muscle activation, strength development, and muscle re-education...
-
Innovaccer Brings Gravity to Infusion as $100B Market Outgrows Its Manual Workflows
SAN FRANCISCO--(BUSINESS WIRE)--Innovaccer today announced that Gravity, its healthcare-native AI platform, is now configured for the infusion access workflow. Gravity for Infusion applies the same platform behind Innovaccer's health system and payer deployments to the administrative steps that sit between an infusion referral and a patient's first treatment. Working on top of a provider's existing EHR, pharmacy, and payer systems, Gravity brings referral, clinical, and coverage information int...